S. J. Zost

Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition

This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

Protective pan-ebolavirus combination therapy by two multifunctional human antibodies

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface

The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

Identification of antibodies targeting the H3N2 hemagglutinin receptor binding site following vaccination of humans

This study identifies H3N2 HA RBS-targeting antibodies in humans, showing some can be broadly reactive despite sensitivity to substitutions near the RBS.

Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin

The paper maps how amino-acid mutations in influenza's hemagglutinin affect neutralization by polyclonal human sera, showing individual variation in escape mutations not observed in ferrets.